Hormonal contraception: What kind, when, and for whom?;Hormonale kontrazeption - Was, wann, für wen?

Deutsches Arzteblatt

Volumn 108, Issue 28-29, 2011, Pages 495-506

  Wiegratz, Inka ^a   Thaler, Christian J ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; GONADOTROPIN; ORAL CONTRACEPTIVE AGENT;

BREAKTHROUGH BLEEDING; CARDIOVASCULAR DISEASE; ENDOMETRIUM CANCER; GERMANY; HORMONAL CONTRACEPTION; HUMAN; OVARY CANCER; OVARY FOLLICLE; OVULATION; PAPILLOMAVIRUS INFECTION; PREGNANCY; REVIEW; RISK FACTOR; THROMBOEMBOLISM; UTERINE CERVIX CANCER;

CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; DRUG IMPLANTS; DRUG TOXICITY; FEMALE; GERMANY; HUMANS; INJECTIONS, INTRAMUSCULAR; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; PAPILLOMAVIRUS INFECTIONS; PREGNANCY; PREGNANCY, UNWANTED; PROGESTERONE CONGENERS; RISK FACTORS; THROMBOEMBOLISM; UTERINE CERVICAL NEOPLASMS;

EID: 80053242383     PISSN: 00121207     EISSN: 01722107     Source Type: Journal    
DOI: 10.3238/arztebl.2011.0495     Document Type: Review

References (25)

1. WHO. Medical elegibility criteria for contraceptive use. 4th ed. Geneva: WHO; 2009. www.who.int/reproductivehealth/publications/fami ly-planning/ 9789241563888/en/
2. Kuhl H: Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005; 8(Suppl1): 3-63.
3. Dinger J, Minh TD, Buttmann N, Bardenheuer K: Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011; 117: 33-40.
4. Rosenberg M, Waugh MS: Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol 1999; 180: 276-9.
5. Mansour D, Inki P, Gemzell-Danielson K: Efficacy of contraceptive methods: a review of the literature. Eur J Contracept Reprod Health Care 2010; 15: 4-16.
6. Guilbert E, Black A, Dunn S, et al.: Missed hormonal contraceptives: new recommendations. J Obstet Gynaecol Can 2008; 30: 1050-62.
7. Wiegratz I, Kuhl H: Long-cycle treatment with oral contraceptives. Drugs 2004; 64: 2447-62. (Pubitemid 39472631)
8. Contin M, Albani F, Ambrosetto G, et al.: Variation in lamotrigine plasma concentrations with hormonal contraceptive monthly cycles in patients with epilepsy. Epilepsia 2006; 47: 1573-5. (Pubitemid 44393872)
9. ESHRE Capri Workshop Group: Female contraception over 40. Hum Reprod Update 2009; 15: 265-77.
10. Heinemann LAJ, Dinger JC: Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007; 75: 328-36. (Pubitemid 46551070)
11. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C: Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890.
12. Emmerich J, Rosendaal FR, Cattaneo M, et al.: Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86: 809-16. (Pubitemid 32834190)
13. Hannaford PC: Epidemiology of the contraceptive pill and venous thromboembolism. Thromb Res 2011; 127(Suppl 3): 30-34.
14. Farley TM, Collins J, Schlesselman JJ: Hormonal contraception and risk of cardiovascular disease. An international perspective. Contraception 1998; 57: 211-30. (Pubitemid 29281907)
15. Etminan M, Takkouche B, Isorna FC, Samii A: Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 2005; 330: 63.
16. La Vecchia C, Bosetti C: Oral contraceptives and neoplasms other than breast and female genital tract. Eur J Cancer Prev 2009; 18: 407-11.
17. Hannaford PC, Selvaraj S, Elliott A, Angus V, Iversen L, Lee AJ: Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioners' oral contraception study. BMJ 2007; 335: 651.
18. Vessey M, Painter R: Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006; 95: 385-9. (Pubitemid 44187603)
19. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-27.
20. Cibula D, Gompel A, Mueck AO, et al.: Hormonal contraception and risk of cancer. Hum Reprod Update 2010; 16: 631-50.
21. Collaborative Group on Epidemiological Studies of Ovarian Cancer: Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371: 303-14.
22. Vessey M, Yeates D, Flynn S: Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception 2010; 82: 221-9.
23. Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ: Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ 2010; 340: c927. doi:10.1136/bmj.c927.
24. Wiegratz I, Kuhl H: Langzyklus. Stuttgart: Thieme 2010; 1-76.
25. Piaggio G, Kapp N, Von Hertzen H: Effect on pregnancy rates of the delay in the administration of levonorgestrel for emergency contraception: a combined analysis of four WHO trials. Contraception 2011, article in press.